Evidence map›Paper›PMID 26680372›Full record

ReviewTransplantation2016

The Influence of Immunosuppressive Agents on the Risk of De Novo Donor-Specific HLA Antibody Production in Solid Organ Transplant Recipients.

Jacqueline G OʼLeary, Millie Samaniego, Marta Crespo Barrio, Luciano Potena, Adriana Zeevi, Arjang Djamali, Emanuele Cozzi

Registry-linked trialOpen access · hybridAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Transplantation, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04444843 (A Multicenter Clinical Trial), which is not on this map. Cited by 42 papers.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed
12.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04444843 phase4unknown statusnot on this mapstarted 2021, after this paper: background citation

A Multicenter Clinical Trial: Risk Factors of Chinese Kidney Transplant Recipients DSA Based on MPA Immunosuppressive Regimen

TypeinterventionalSponsorFirst Affiliated Hospital Xi'an Jiaotong UniversityRan2021 to 2023Enrolled300ConditionsKidney Transplant RecipientsArmsMycophenolate Mofetil Capsules
3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 112 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Excellent efficacy and beneficial safety during observational 5-year follow-up of rapid steroid withdrawal after renal transplantation (Harmony FU study).Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2023
    Article
  10. Review
  11. Article
  12. Review
  13. Everolimus plus reduced calcineurin inhibitor preventsFrontiers in transplantation · 2023
    Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Therapies for Chronic Allograft Rejection.Frontiers in pharmacology · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Jacqueline G OʼLeary1 Annette C. and Harold C. Simmons Transplant Institute, Baylor University Medical Center, Dallas, TX.2 Department of Internal Medicine, Nephrology, University of Michigan, Ann Arbor, MI.3 Nephrology Department and Renal Transplant Unit, Hospital del Mar, Parc de Salut Mar, Institut Hospital del Mar d'Investigacions Mèdiques, Barcelona, Spain.4 Heart and Lung Transplant Program, Department of Experimental and Specialty Medicine, Academic Hospital S. Orsola-Malpighi, University of Bologna, Bologna, Italy.5 Pathology Department, University of Pittsburgh Medical Center, Pittsburgh, PA.6 Division of Nephrology, University of Wisconsin School of Medicine and Public Health, Madison, WI.7 Transplantation Immunology, Department of Transfusion Medicine, Padua University Hospital, Padua, Italy.
Millie Samaniego
Marta Crespo Barrio
Luciano Potena
Adriana Zeevi
Arjang Djamali
Emanuele Cozzi
Baylor University Medical Center · USUniversity of Wisconsin–Madison · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Production of de novo donor-specific antibodies (dnDSA) is a major risk factor for acute and chronic antibody-mediated rejection and graft loss after all solid organ transplantation. In this article, we review the data available on the risk of individual immunosuppressive agents and their ability to prevent dnDSA production. Induction therapy with rabbit antithymocyte globulin may achieve a short-term decrease in dnDSA production in moderately sensitized patients. Rituximab induction may be beneficial in sensitized patients, and in abrogating rebound antibody response in patients undergoing desensitization or treatment for antibody-mediated rejection. Use of bortezomib for induction therapy in at-risk patients is of interest, but the benefits are unproven. In maintenance regimens, nonadherent and previously sensitized patients are not suitable for aggressive weaning protocols, particularly early calcineurin inhibitor withdrawal without lymphocyte-depleting induction. Early conversion to mammalian target of rapamycin inhibitor monotherapy has been reported to increase the risk of dnDSA formation, but a combination of mammalian target of rapamycin inhibitor and reduced-exposure calcineurin inhibitor does not appear to alter the risk. Early steroid therapy withdrawal in standard-risk patients after induction has no known dnDSA penalty. The available data do not demonstrate a consistent effect of mycophenolic acid on dnDSA production. Risk minimization for dnDSA requires monitoring of adherence, appropriate risk stratification, risk-based immunosuppression intensity, and prospective DSA surveillance.

Indexed as

HistocompatibilityAnimalsBiomarkersDrug Therapy, CombinationGraft RejectionGraft SurvivalHistocompatibility TestingHLA AntigensHumansImmunosuppressive AgentsIsoantibodiesOrgan TransplantationRisk AssessmentRisk FactorsTreatment OutcomeBiomarkersHLA AntigensImmunosuppressive AgentsIsoantibodies

Identifiers

PMID26680372
PMCPMC4683034
OpenAlexW2266063425

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.